NeuClone Pharmaceuticals Ltd

Johnson & Johnson has a host of biosimilar rivals on the horizon each wanting a slice of its $9.7bn Stelara (ustekinumab) sales pie and until recently, biosimilars industry analysts had predicted tha

Australian biosimilar monoclonal antibodies specialist NeuClone has revealed that it is developing biosimilar versions of Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck Sharp & Dohme’s Keytruda